KPV Capsules, Cream or Injection? Route, Evidence and What the HHS Policy Covers

KPV is sold three ways: capsules, creams and injectable vials. Since October 28, 2026, the route matters for regulation as well as medicine. Under a draft HHS enforcement policy announced that day, HHS says it does not intend to take action against 503A pharmacies that compound KPV acetate under ten conditions, and only in topical and oral dosage forms^[1]. The policy is not final and is not binding on HHS or the public, and comments are open until November 13, 2026^[12]. Injectable KPV is outside the policy. Oral products carry an extra condition: the compounder must keep documentation that the specific formulation reaches adequate oral bioavailability in humans^[1]. We found no published human study measuring how much oral or topical KPV the body absorbs. The route evidence that does exist comes from mice, rats, cell cultures and lab skin samples, and it points in a clear direction: KPV is taken up in the gut by a peptide transporter, and it barely crosses intact skin on its own^[2][7]. KPV is not FDA-approved, and no human trial has shown it treats any condition.

The short answer

What KPV is, briefly

KPV is three amino acids, lysine-proline-valine, the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH). HHS lists KPV acetate with a molecular weight of 402.5 g/mol^[1]. In lab and animal studies, nanomolar concentrations of KPV blocked NF-kappaB and MAP kinase inflammatory signaling and reduced inflammatory cytokines^[2]. That anti-inflammatory signal is why it is marketed for gut and skin conditions.

Oral KPV and KPV capsules

Oral KPV has the strongest route rationale of the three, because of a transporter called PepT1. PepT1 moves small peptides of two or three amino acids into cells. It is normally expressed in the small intestine and is induced in the colon during inflammatory bowel disease. In a 2008 study, KPV was carried into human intestinal and immune cells by PepT1, and KPV added to the drinking water of mice reduced chemically induced colitis^[2]. A 2016 study sharpened the point: KPV protected normal mice against colitis-associated tumors but had no effect in mice lacking PepT1^[5].

Delivery still matters. The same research group packed KPV into nanoparticles inside a polysaccharide gel that releases in the colon, and reported similar benefit in mouse colitis at a concentration 12,000-fold lower than KPV in free solution^[3]. A 2017 study used hyaluronic acid-coated nanoparticles taken by mouth, again in mice, and reported less mucosal damage and lower TNF-alpha^[4]. Those are engineered research formulations. A compounded capsule of plain KPV acetate is a different product, and none of these studies measured how much of a plain capsule reaches the blood or the colon in people.

That gap is exactly what the HHS policy asks pharmacies to close. Condition 8 reads: “Achieving adequate oral bioavailability of peptides is inherently difficult and complex. Therefore, if a peptide is compounded in an oral dosage form, the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.”^[1] The policy does not define “adequate,” and we found no published human data a pharmacy could point to for KPV. If you are prescribed KPV capsules, it is reasonable to ask the pharmacy what documentation it holds for that formulation.

Topical KPV: creams and gels

The most useful study for topical KPV tested it on dermatomed human skin in the lab. By simple passive diffusion, KPV permeation was below the detection limit of 0.01 micrograms per milliliter. Pretreating the skin with microneedles raised permeation to 4.4 micrograms per square centimeter per hour, and adding iontophoresis (a small electrical current) raised it 8-fold, or 35-fold with microneedles, compared with microneedles alone^[7]. In plain terms: on intact skin, a simple KPV cream may deliver very little of the peptide past the outer layer. How much of this applies to broken or inflamed skin was not tested.

KPV's effects on skin cells themselves are better documented, though still preclinical. In human keratinocytes exposed to fine dust, 50 micrograms per milliliter of KPV restored cell viability, reduced the inflammatory signal IL-1beta and limited cell death, including in a three-dimensional skin model^[9]. In rats with chemotherapy-induced mouth sores, a KPV-loaded hydrogel that sticks to the gums improved food intake and weight recovery^[10]. Stability is another formulation question: under acid, alkali and peroxide stress, KPV breaks down mainly to a lysine-proline diketopiperazine^[8], so how a cream is made and stored matters.

Injectable KPV

KPV is also sold as an injectable vial, but injection is not covered by the HHS policy^[1]. A pharmacy that compounds KPV for injection gets no enforcement-discretion cover from the policy. The evidence does not offer a strong reason to prefer injection either: the best-characterized mouse colitis studies gave KPV by mouth^[2][3], other colitis studies do not state the route in their abstracts^[6], and there is no human injection study. If you are offered injectable KPV after October 2026, the offer itself tells you the product sits outside the federal policy. The same applies to KPV inside injectable blends such as the KLOW peptide blend.

What the policy requires for any KPV product

• KPV acetate, topical or oral only, made from bulk drug substance with a certificate of analysis that meets the policy's testing standard^[1].
• A patient-specific prescription, filled by a State-licensed pharmacy, a Federal facility or a licensed physician^[1].
• A single active ingredient. Blends that combine KPV with BPC-157, TB-500 or GHK-Cu do not qualify^[1].
• A label reading “This is a compounded drug product. Not for resale.”, and reporting of serious adverse events and quality problems to FDA MedWatch^[1].
• For oral forms, documented adequate oral bioavailability in humans for that specific formulation^[1].

HHS's stated reasons for covering KPV were documented single-ingredient use, new lot data confirming identity and reporting endotoxin and microbial results, and its view that CDER's safety conclusion “reflects an absence of information rather than an observed signal”^[1]. That last phrase is worth reading slowly: it means the safety record is empty, not clean. An independent review of the advisory committee's peptide decisions appears in the pharmacy compounding literature^[11]. The full policy is in our explainer, with the announcement covered in our news report.

Morning or night?

No study has tested KPV timing in people, and the animal studies were not designed to answer it. Any morning-or-night advice is guesswork. Timing, like strength, is a prescriber decision under the HHS policy.

Bottom line

The HHS policy lines up with the route evidence better than with the market. KPV's best-supported route is oral, through the PepT1 transporter in the gut, but only in mice^[2][5], and the policy asks pharmacies to document human oral bioavailability that the published literature does not yet contain^[1]. Topical KPV is covered, but plain KPV barely crosses intact human skin in the lab^[7]. Injectable KPV is not covered at all. Our KPV provider page lists every seller we confirmed sells KPV as a single-ingredient product, shows the form each one sells, and labels injectable KPV as a form the policy does not cover; blends are left off. A listing does not confirm that the pharmacy meets the policy’s other conditions, so check the list above yourself: a certificate of analysis, a single active ingredient, the label line, a topical or oral form (with bioavailability documentation for capsules), a 510(k)-cleared syringe as the only device if any is included, and a State-licensed 503A pharmacy. Related reading: semax nasal spray, where the policy also allows a single route, and TB-500 side effects and safety. For stacking risks, see peptide stacking safety.